NASDAQ · Biotechnology

Ernexa Therapeutics Inc. (ERNA) Stock

$2.40 -3.61% NASDAQ: ERNA Healthcare

Valuation

MetricValue
Price$2.40
Market Cap$3.92M
P/E Ratio-0.15
P/B Ratio1.02
P/S Ratio0.00
EPS (TTM)$-56.00
52-Week High$71.50
52-Week Low$2.24
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-305.85%
ROA-194.09%
ROCE-346.94%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.11
Current Ratio1.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$1.0M$0
Operating Profit$-114.0M$-33.0M$-21.0M$-16.0M$-9.0M
Net Profit$-123.0M$-25.0M$-22.0M$-45.0M$-14.0M
EPS$-1415.25$-201.50$-102.00$-39.25$-56.00
Op Margin——-31080.9%-2693.1%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$32.0M$22.0M$49.0M$5.0M$6.0M
Total Liabilities$6.0M$10.0M$47.0M$4.0M$3.0M
Cash$17.0M$11.0M$8.0M$2.0M$2.0M
Borrowings$3.0M$4.0M$42.0M$1.0M$0

Latest News

Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) InvestorsHub · Jul 15, 2026 Ernexa Therapeutics Says Preclinical Data Shows Anti-Tumor Activity of ERNA-101 Combination MT Newswires · Jul 15, 2026 Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry GlobeNewswire · Jul 15, 2026 Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 GlobeNewswire · Jul 14, 2026 Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients GlobeNewswire · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-23.0M$-21.0M$-20.0M$-16.0M$-7.0M
Investing Cash Flow$-23.0M$0$0$-1.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$15.0M$-1.0M$-4.0M$-10.0M$0
Free Cash Flow$-24.0M$-21.0M$-20.0M$-16.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.01
FCF Yield-197.05%
Quick Ratio2.01
Interest Coverage-378.61
Return 1Y-85.98%
Return 3Y-99.36%
Return 5Y-99.99%

Ownership

Insiders Held41.74%
Institutions Held10.16%
Institutions Float Held17.44%
Institutional HolderSharesReport Date
Bleichroeder LP80,0002026-03-31
Dauntless Investment Group, LLC 24,4982026-03-31
Corient Private Wealth LLC17,5242026-03-31
Geode Capital Management, LLC9,7782026-03-31
Xtx Topco Ltd2,1742026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAPAdaptimmune Therapeutics plc $0.05 -3.00% -0.16 $75.16M 0.00%
AEMDAethlon Medical, Inc. $6.05 +0.67% -0.55 $3.19M 0.00%
AEONAEON Biopharma, Inc. $0.28 -10.97% -0.08 $12.19M 0.00%
DWTXDogwood Therapeutics, Inc. $1.40 -0.71% -0.18 $47.08M 0.00%
LNAILunai Bioworks Inc. $1.23 +9.82% -0.02 $5.58M 0.00%

About Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc. is led by CEO Sanjeev Luther, employs 6 people, headquartered in US, publicly traded since 1991.

Ernexa Therapeutics Inc. (ERNA) stock trades at $2.40 with a market capitalization of $3.92M. The stock is valued at a price-to-earnings (P/E) ratio of -0.15, price-to-book of 1.02, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.24 and $71.50, and currently trades 96.6% below its 52-week high.

On profitability, Ernexa Therapeutics Inc. generates a return on equity (ROE) of -305.85%, return on capital employed of -346.94%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides